Bayer announced on Tuesday that it plans to file marketing approvals for elinzanetant, its experimental treatment for symptoms associated with menopause, following further positive phase 3 results.

The German pharmaceutical group reports that the 'Oasis 3' study met its primary endpoint, demonstrating a statistically significant reduction in the frequency and severity of moderate to severe vasomotor symptoms compared to placebo in postmenopausal women.

The study involved 628 women aged 40 to 65 over a 52-week period at nine research sites in nine countries.

In view of the already favorable conclusions of the other two phase III studies, Oasis 1 and 2, Bayer says it is now considering filing registration dossiers with health authorities worldwide.

Elinzanetant, a once-daily oral tablet, acts on hot flushes by modulating sensitive neurons which, with decreasing estrogen levels, become hypertrophic and lead to hyperactivation of the thermoregulatory system.

Elinzanetant is also thought to reduce sleep disturbances associated with menopause.

Copyright (c) 2024 CercleFinance.com. All rights reserved.